Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Angiodynamics (ANGO) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Angiodynamics (ANGO) over the last 17 years, with Q4 2025 value amounting to $108.3 million.

  • Angiodynamics' Non-Current Assets fell 680.32% to $108.3 million in Q4 2025 from the same period last year, while for Nov 2025 it was $442.3 million, marking a year-over-year decrease of 967.0%. This contributed to the annual value of $111.8 million for FY2025, which is 1012.55% down from last year.
  • Angiodynamics' Non-Current Assets amounted to $108.3 million in Q4 2025, which was down 680.32% from $109.0 million recorded in Q3 2025.
  • In the past 5 years, Angiodynamics' Non-Current Assets ranged from a high of $436.6 million in Q1 2021 and a low of $108.3 million during Q4 2025
  • Moreover, its 5-year median value for Non-Current Assets was $343.8 million (2023), whereas its average is $282.9 million.
  • Per our database at Business Quant, Angiodynamics' Non-Current Assets plummeted by 265.19% in 2022 and then plummeted by 6721.93% in 2024.
  • Quarter analysis of 5 years shows Angiodynamics' Non-Current Assets stood at $421.9 million in 2021, then decreased by 5.34% to $399.4 million in 2022, then decreased by 21.34% to $314.2 million in 2023, then plummeted by 63.0% to $116.2 million in 2024, then dropped by 6.8% to $108.3 million in 2025.
  • Its Non-Current Assets stands at $108.3 million for Q4 2025, versus $109.0 million for Q3 2025 and $111.8 million for Q2 2025.